Research programme: anti-COVID-19 therapeutics - Elasmogen
Alternative Names: Anti-COVID-19 therapeutics - ElasmogenLatest Information Update: 28 Feb 2025
At a glance
- Originator Elasmogen
- Developer Elasmogen; University of Minnesota
- Class Antivirals; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in United Kingdom
- 28 Feb 2025 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA
- 29 Jan 2021 Early research in COVID-2019 infections (Prevention) in United Kingdom, prior to January 2021